The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Among the upcoming haematology meeting’s non-oncology presentations Uniqure’s haemophilia B gene therapy scores a valuable late-breaker.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.